2024-03-29T11:51:16Zhttp://digital.csic.es/dspace-oai/requestoai:digital.csic.es:10261/2369712022-05-20T10:36:34Zcom_10261_35com_10261_5com_10261_2288com_10261_9col_10261_288col_10261_204074
00925njm 22002777a 4500
dc
Santiago, Llipsy
author
Uranga Murillo, Iratxe
author
Arias, Maykel
author
González Ramírez, Andrés Manuel
author
Macías-León, Javier
author
Moreo, Eduardo
author
Redrado, Sergio
author
García García, Ana
author
Taleb, V.
author
Lira-Navarrete, Erandi
author
Hurtado-Guerrero, R.
author
Aguiló, Nacho
author
Encabo-Berzosa, M. Mar
author
Hidalgo, Sandra
author
Gálvez Buerba, Eva Mª
author
Ramírez-Labrada, Ariel
author
Miguel, Diego de
author
Benito, Rafael
author
Miranda, Patricia
author
Fernández Casanovas, Antonio
author
Domingo, José María
author
Serrano Barcos, Laura
author
Yuste, Cristina
author
Villanueva-Saz, Sergio
author
Paño, José Ramón
author
Pardo, Julián
author
2021-03-10
Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Nevertheless, its efficacy in patients with COVID-19 remains uncertain. Thus, the establishment and validation of standardized methods that predict the viral neutralizing (VN) activity of plasma against SARS-CoV-2 is of utmost importance to appraise its therapeutic value. Using an in-house quantitative ELISA test and two independent cohorts with a total of 345 donors, we found that plasma and serum from most convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, with varying concentrations which correlate with previous disease severity and gender. Anti-RBD IgG plasma concentration significantly correlated with the plasma/serum VN activity against SARS-CoV-2 in vitro.
Several hundred millions of people have been diagnosed of coronavirus disease 2019 (COVID-19), causing millions of deaths and a high socioeconomic burden. SARS-CoV-2, the causative agent of COVID-19, induces both specific T- and B-cell responses, being antibodies against the virus detected a few days after infection. Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Using an in-house quantitative ELISA test, we found that plasma from 177 convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, although at very different concentrations which correlated with previous disease severity and gender. Anti-RBD IgG plasma concentrations significantly correlated with the plasma viral neutralizing activity (VN) against SARS-CoV-2 in vitro. Similar results were found using an independent cohort of serum from 168 convalescent health workers. These results validate an in-house RBD IgG ELISA test in a large cohort of COVID-19 convalescent patients and indicate that plasma from all convalescent donors does not contain a high enough amount of anti-SARS-CoV-2-RBD neutralizing IgG to prevent SARS-CoV-2 infection in vitro. The use of quantitative anti-RBD IgG detection systems might help to predict the efficacy of the passive immunization using plasma from patients recovered from SARS-CoV-2.
Biology 10(3): 208 (2021)
http://hdl.handle.net/10261/236971
10.3390/biology10030208
2079-7737
http://dx.doi.org/10.13039/501100011033
http://dx.doi.org/10.13039/501100007041
http://dx.doi.org/10.13039/501100004587
http://dx.doi.org/10.13039/100008049
http://dx.doi.org/10.13039/501100000780
http://dx.doi.org/10.13039/501100010067
33801808
Coronavirus
SARS-CoV-2
IgG
Antibodies
Convalescent plasma
ELISA
Determination of the concentration of IgG against the spike receptor-binding domain that predicts the viral neutralizing activity of convalescent plasma and serum against SARS-CoV-2